Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | RO7296682 |
Synonyms | |
Therapy Description |
RO7296682 is a monoclonal antibody that recognizes CD25 (IL-2R alpha) on regulatory T lymphocytes (Tregs), potentially leading to Treg depletion and increased anti-tumor immune response (NCI Drug Dictionary) |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
RO7296682 | RO-7296682|RO 7296682 | RO7296682 is a monoclonal antibody that recognizes CD25 (IL-2R alpha) on regulatory T lymphocytes (Tregs), potentially leading to Treg depletion and increased anti-tumor immune response (NCI Drug Dictionary) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04158583 | Phase I | RO7296682 | A Study to Evaluate the Safety and Tolerability of RO7296682 in Participants With Advanced Solid Tumors. | Terminated | ESP | DNK | CAN | BEL | AUS | 0 |